Drilling Down Into Immunomedics, Inc. (IMMU)

Immunomedics, Inc. (IMMU) is an interesting player in the Healthcare space, with a focus on Biotechnology. The stock has been active on the tape, currently trading at $16.16, down from yesterday’s close by -0.98%. Given the stock’s recent action, it seemed like a good time to take a closer look at the company’s recent data.

Fundamental Analysis

Immunomedics, Inc. (IMMU) currently trades with a market capitalization of $2.48 Billion. That value represents a market adjusting for revenues that have been falling by -6.92 % on a quarterly year/year basis as of the company’s last quarterly report.

You can get a sense of how sustainable that is by a levered free cash flow of -$67.99 Million over the past twelve months. Generally speaking, earnings are expected to hold steady in coming quarters. Analysts are forecasting earnings of -$0.12 on a per share basis this quarter. Perhaps, that suggests something about why 1.16% of the outstanding share supply is held by institutional investors.

Technical Analysis

No analysis is ever complete without a thorough survey of a stock’s technical behavior. Looking at the stock’s movement on the chart, Immunomedics, Inc. recorded a 52-week high of $16.47. It is now trading 0.31% off that level. The stock is trading $11.72 its 50-day moving average by -4.44%. The stock carved out a 52-week low down at $3.30.

In recent action, Immunomedics, Inc. (IMMU) has made a move of +48.80% over the past month, which has come on Strong relative transaction volume. Over the trailing year, the stock is underperforming the S&P 500 by 19.03, and it’s gotten there by action that has been more volatile on a day-to-day basis than most other stocks on the exchange. In terms of the mechanics underlying that movement, traders will want to note that the stock is trading on a float of 17.23% with $142.78 Million sitting short, betting on future declines. That suggests something of the likelihood of a short squeeze in shares of IMMU.

Previous articleLouisiana-Pacific Corporation (LPX): From Top to Bottom
Next articleThe Case for and Against Fifth Third Bancorp (FITB)